Save Product
Product Details
Specificity
Specifically recognizes PBD.
Source
Monoclonal Anti-Payload PBD Antibody, Rabbit IgG (M1D08) is a Rabbit monoclonal antibody recombinantly expressed from HEK293 cells.
Clone
M1D08
Isotype
Rabbit IgG | Rabbit Kappa
Conjugate
Unconjugated
Immunogen
PBD-BSA
Application
ApplicationRecommended UsageELISA0.06-10000 ng/mLPurification
Protein A purified / Protein G purified
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-ELISA
Immobilized Monoclonal Anti-Payload PBD Antibody, Rabbit IgG (M1D08) (Cat. No. PAD-MY2221) at 1 μg/mL, add Loncastuximab Tesirine in the 100% Human Serum and then add Biotinylated Human CD19 (20-291), His,Avitag, premium grade (Cat. No. CD9-H82E9) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (QC tested).
Protocol
Serial dilutions of (PBD)SG3199 were added into Monoclonal Anti-Payload PBD Antibody, Rabbit IgG (M1D08) (Cat. No. PAD-MY2221): Loncastuximab Tesirine binding reactions. The half maximal inhibitory concentration (IC50) is 0.7587 μg/mL (Routinely tested).
Protocol
Cross Verification
ELISA binding of Monoclonal Anti-Payload PBD Antibody, Rabbit IgG (M1D08) (Cat. No. PAD-MY2221) with Loncastuximab Tesirine, Disitamab Vedotin (RC48), IgG1-MMAF, Trastuzumab Deruxtecan, Sacituzumab Govitecam and Trastuzumab-DM1 conjugated antibody respectively.
The coating antibody was Monoclonal Anti-Payload PBD Antibody, Rabbit IgG (M1D08) (Cat. No. PAD-MY2221), used at 1 μg/mL concentration. The primary antibody were different payload conjugated antibodies, including Loncastuximab Tesirine, Disitamab Vedotin (RC48), IgG1-MMAF, Trastuzumab Deruxtecan, Sacituzumab Govitecam and Trastuzumab-DM1 conjugated antibodies used at 0.25 μg/mL concentration. The secondary antibody was HRP conjugated Anti-Human-IgG-Fc Antibody (6F11C8), mAb (Acro, Cat. No. IGG-LY69) used at 1:10000 concentration.
Monoclonal Anti-Payload PBD Antibody, Rabbit IgG (M1D08) (Cat. No. PAD-MY2221) is specific to Loncastuximab Tesirine and has no cross-reactivity with IgG1-MMAF, Disitamab Vedotin (RC48), Trastuzumab Deruxtecan, Sacituzumab Govitecam and Trastuzumab-DM1 (Routinely tested).
Customer Reviews Writing Reviews
Background
Recent Advances
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing